Blocking CD200R to improve cancer immunotherapy
Official title: CD200R blockade for cancer immunotherapy
Funded at Ohio State University · NIH-10980744 · Data updated 2026-11-12
This study is looking at a new way to boost cancer treatment by blocking a specific immune receptor called CD200R, which could help your immune system fight tumors better, especially if you have advanced cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $559,062 |
| NIH project number | 1R01CA285726-01A1 |
| Project ID | NIH-10980744 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced cancers who are seeking new treatment options.
✕Less likely to help
Patients with early-stage cancers or those who do not express CD200+ tumors may not benefit from this research.
What this research studies
This research investigates the potential of blocking the CD200R immune receptor to enhance the effectiveness of cancer immunotherapy. By targeting both T cells and myeloid cells in the tumor microenvironment, the study aims to improve the immune response against tumors. The approach involves using antibody therapeutics to inhibit CD200R, which has shown promise in preclinical models. Patients with advanced cancers may benefit from this innovative treatment strategy as it seeks to optimize immune cell activity against tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with advanced cancers.
How similar studies have gone: Other research has shown promising results with similar immune checkpoint blockade approaches, indicating potential for success in this area.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Basu, Sujit — Ohio State University
- Study coordinator: Basu, Sujit
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.